News - Anti-virals, Financial

Filter

Current filters:

Anti-viralsFinancial

Popular Filters

1 to 25 of 38 results

The price of NOT curing hepatitis C - by Robert Zirkelbach

The price of NOT curing hepatitis C - by Robert Zirkelbach

20-07-2014

Over the past few months, there has been increased focus on the price of a new cure for hepatitis C,…

Anti-viralsBiotechnologyFinancialHealthcareHepatitis CHepatitis CLiver transplantsMedicineTradeUSA

Report: US state governments may spend $55 billion on hepatitis C drugs

Report: US state governments may spend $55 billion on hepatitis C drugs

17-07-2014

State legislatures in the USA will need to find billions in their budgets to purchase costly new hepatitis…

Anti-viralsExpress ScriptsFinancialGilead SciencesHealthcarePharmaceuticalSovaldiUSA

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

03-07-2014

USA-based Isis Pharmaceuticals has earned yet another $1 million payment from UK pharma giant GlaxoSmithKline,…

Anti-viralsFinancialGlaxoSmithKlineIsis PharmaceuticalsPharmaceuticalResearch

AbbVie opens expanded manufacturing facility in Ireland

AbbVie opens expanded manufacturing facility in Ireland

03-06-2014

The chairman and chief of US drugmaker AbbVie, Richard Gonzalez, accompanied by other senior executives,…

AbbVieAnti-viralsFinancialIrelandPharmaceuticalProduction

Biota Pharma plans restructuring following loss of BARDA contract

02-06-2014

USA-based Biota Pharmaceuticals has adopted a plan to restructure the company's operations following…

Anti-viralsBiota PharmaceuticalsBiotechnologyFinanciallaninamivirManagementUSA

Gilead 1st-qtr 2014 sales nearly double, fuelled by Sovaldi, as net income rockets

23-04-2014

US antivirals major Gilead Sciences posted first-quarter 2014 results after markets closed yesterday,…

Anti-viralsBiotechnologyFinancialGilead SciencesSovaldi

AbbVie files NDA for oral, interferon-free treatment of hepatitis C

22-04-2014

US drugmaker AbbVie has submitted its New Drug Application to the US Food and Drug Administration for…

AbbVieAnti-viralsEnanta PharmaceuticalsFinancialNorth AmericaPharmaceuticalRegulationUSA

NHS England agrees funding for Gilead’s hepatitis C drug Sovaldi

18-04-2014

NHS England has approved an £18.7 million ($31.3 million) investment in a new drug for the treatment…

Anti-viralsBiotechnologyFinancialGilead SciencesHealthcareNorthern EuropeSovaldiUK

Pharma Summit: AIDS activists picket to demand South African reform

Pharma Summit: AIDS activists picket to demand South African reform

14-03-2014

Delegates at The Economist’s Pharma Summit in London yesterday were greeted by AIDS activists picketing…

Anti-viralsFinancialLegalPharmaceuticalPricingSouth AfricaUK

iCo Therapeutics within reach of ‘holy grail’ cure in the $14 billion HIV market, says Edison

20-01-2014

Canadian biotech company iCo Therapeutics’s (iCO: TSX-V) compound AmpB could potentially allow the…

Anti-viralsBiotechnologyCanadaFinancialiCo TherapeuticsResearch

Catalyst-rich period ahead for key trial results from BioLineRx

09-12-2013

Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…

Anti-viralsBioLineRxBL-1040BL-8020BL-8040Cardio-vascularFinancialOncologyPharmaceuticalResearch

Vertex sells Incivo royalty rights to Janssen for $152 million

21-11-2013

Loss-making US biotech firm Vertex Pharmaceuticals says that it has sold its product royalty rights relating…

Anti-viralsBiotechnologyFinancialIncivoJanssenJohnson & JohnsonLicensingVertex

New HIV drugs drive Gilead Sciences 3rd-qtr growth

New HIV drugs drive Gilead Sciences 3rd-qtr growth

30-10-2013

US biotech Gilead Sciences late yesterday reported strong third-quarter 2013 financial results that were…

Anti-viralsBiotechnologyFinancialGilead Sciences

DC AIDS protesters join push to demand China gives $1 billion to fight global AIDS

25-10-2013

The Washington DC, USA based AIDS Healthcare Foundation (AHF) is spearheading a series of US and global…

Anti-viralsAsia-PacificFinancialPharmaceuticalPolitics

HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst

20-05-2013

While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing a preventative…

Anti-viralsBiotechnologyFinancialHVTN 505PharmaceuticalResearchVaccines

Gilead's 1st-qtr profits rocket 63% on 11% revenue rise; moves forward with hep C program

03-05-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has reported that revenues for the first quarter of 2013…

Anti-viralsBiotechnologyFinancialGilead SciencesledipasvirResearchsofosbuvir

Specialty drug costs account for over 50% of the total cost of care for RA and hepatitis C patients in USA

03-04-2013

According to two new studies by Prime Therapeutics, a leading US pharmacy benefit manager, rheumatoid…

Anti-Arthritics/RheumaticsAnti-viralsBiotechnologyFinancialHealthcareNorth AmericaPharmaceutical

Australia to subsidize groundbreaking hepatitis C drugs under PBS

19-02-2013

The Australian government said on February 19 that it is extended subsidies of important medicines each…

Anti-viralsAsia-PacificFinancialHealthcareIncivoJohnson & JohnsonMerck & CoPharmaceuticalPricingVictrelis

Gilead 4th-qtr sales and earnings beat forecasts, but slammed for "greed" by AHF

05-02-2013

USA-based Gilead Sciences (Nasdaq: GILD), the leading maker of HIV/AIDS drugs, yesterday posted financial…

Anti-viralsBiotechnologyFinancialGilead SciencesPricing

News briefs: Novartis drops Ruvise MAA; B-MS settlement; Germany donates to Global Fund

25-01-2013

The European Medicines Agency says it has been formally notified by Swiss drug major Novartis (NOVN:…

Anti-viralsBMS-986094Bristol-Myers SquibbFinancialLegalNovartisPharmaceuticalRare diseasesRegulationRuviseTropical diseases

New executive director of the Global Fund outlines ambitious agenda

21-01-2013

Mark Dybul yesterday took charge as executive director of the Global Fund to Fight AIDS, Tuberculosis…

Anti-viralsAntibiotics and Infectious diseasesFinancialManagementPharmaceuticalTropical diseases

New Zealand to fund Gilead's Atripla and Truvada

27-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC says that, effective December 1, it will fund…

Anti-viralsAsia-PacificAtriplaBiotechnologyFinancialGilead SciencesPharmaceuticalRegulationTruvada

Gilead beats forecasts, posting 14% rise in third-quarter 2012 sales

24-10-2012

US antiviral drugs giant Gilead Sciences (Nasdaq: GILD) reported results for the third quarter of 2012,…

Anti-viralsBiotechnologyFinancialGilead Sciences

Arrowhead Research Corp improving focus, say Edison analysts

16-08-2012

Last year's acquisition of Roche's RNAi (RNA interference) business (The Pharma Letter October 25, 2011)…

AdipotideAnti-viralsArrowhead ResearchBiotechnologyFinancialMetabolicsOncologyResearch

1 to 25 of 38 results

Back to top